Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab

AIMS: To evaluate potential differences between PF‐05280586 and rituximab sourced from the European Union (rituximab‐EU) and USA (rituximab‐US) in clinical response (Disease Activity Score in 28 Joints [DAS28] and American College of Rheumatology [ACR] criteria), as part of the overall biosimilarity...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Jason H., Hutmacher, Matthew M., Zierhut, Matthew L., Becker, Jean‐Claude, Gumbiner, Barry, Spencer‐Green, George, Melia, Lisa A., Liao, Kai‐Hsin, Suster, Matthew, Yin, Donghua, Li, Ruifeng, Meng, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Pharmacokinetic Dynamic Relationships
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099556/
https://www.ncbi.nlm.nih.gov/pubmed/27530379
http://dx.doi.org/10.1111/bcp.13094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099556/
https://www.ncbi.nlm.nih.gov/pubmed/27530379
http://dx.doi.org/10.1111/bcp.13094

Ejemplares similares